ARDELYX, INC. announced unaudited U.S. net product sales revenue of IBSRELA of approximately $28 million for Q4 2023 and $80 million for the full year 2023, and net product sales revenue of XPHOZAH of approximately $2.5 million for Q4 2023. The company also reported cash, cash equivalents, and short-term investments of approximately $184 million as of December 31, 2023.